Publications by authors named "Ewa Pacuszka"
Article Synopsis
- - The study investigates the relationship between kisspeptin levels and antenatal complications like hypertensive disorders, fetal growth restriction, gestational diabetes, and preterm birth, analyzing data from 105 women with complications and 265 with normal pregnancies.
- - Findings show that kisspeptin levels vary by condition: higher levels in hypertensive disorders and lower in fetal growth restriction during the third trimester, suggesting a potential link to placental function.
- - The results indicate kisspeptin could serve as a biomarker for antenatal complications, highlighting the need for further research to understand its clinical implications.
Objective: To compare the performance of kisspeptin and beta human chorionic gonadotropin (βhCG), both alone and in combination, as biomarkers for miscarriage throughout the first trimester.
Design: Prospective, nested case-control study.
Setting: Tertiary Centre, Queen Charlotte Hospital, London, United Kingdom.
Context: Glucagon increases energy expenditure; consequently, glucagon receptor agonists are in development for the treatment of obesity. Obesity negatively affects the reproductive axis, and hypogonadism itself can exacerbate weight gain. Therefore, knowledge of the effects of glucagon receptor agonism on reproductive hormones is important for developing therapeutics for obesity; but reports in the literature about the effects of glucagon receptor agonism on the reproductive axis are conflicting.
View Article and Find Full Text PDFContext: Glucagon-like peptide-1 (GLP-1) potently reduces food intake and augments glucose-stimulated insulin secretion. Recent animal data suggest that GLP-1 may also influence reproduction. As GLP-1 receptor agonists are currently widely used in clinical practice to treat obesity/type 2 diabetes, it is necessary to determine the effects of GLP-1 on the reproductive system in humans.
View Article and Find Full Text PDFArticle Synopsis
- * Conducted as a single-blind, randomized, placebo-controlled crossover trial, 18 healthy men received either PYY or a placebo through an eight-hour intravenous infusion.
- * Results showed no significant differences in luteinizing hormone (LH) pulses, levels of LH, follicle stimulating hormone (FSH), or testosterone between the PYY and placebo infusions, suggesting PYY does not affect the reproductive axis in this population.